Skip to main content
OpenTrials
Completed

NCT Number: NCT07255989

Diagnosis of Fatty Pancreas by FibroScan

Example 2: Interventional study The goal of this observational study is to learn know about the use of FibroScan in diagnosis of fatty pancreas in obese and non obese patients which done for the first time at worldwide as well as Egypt .The participtants already came to do liver FibroScan at center of excellence , Benha University , Egypt. Untill now the diagnosis of fatty pancreas by MRI which accurate and specific and diagnose fatty pancreasif it is more than 6.2% . lough the use of abdominal ultrasound also is proved . The use of digital fibroscan which is easy non invasive , unique as well as we can diagnose fibrosis too in the same sitting .So it is highly recommended to be add with examination of liver by fibroscan.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Benha University , Egypt

Banhā, Qalyubia Governorate, 1531, Egypt

About this study

This Interventional study done for subjects attend Center of excellence , at Benha University . aged of patients was from 30 years to 70 years old , both male and females , obese or non and DM or non . the patients came to do fibroscan to liver . Lab investigations in the form of CBC ,ESR , liver function tests , kidney function tests. Complete lipid profile , HbA1c .clincal and physical examinations done as regard BMI, past history for metabolic diseases , operations and blood transfusion. FibroScan done first to liver while the patients fastinf at least 3 hours with the know specific position recommendation (banana like ).The position for pancreas examination by fibroScan differe as the patient dorsal position/ recumbancy and his hand behind his head . take deep breah and slighlty keep it . some tilting to the left or right . the probe of fibroscan in the epigastrium under the left rib.which totally differe than liver which in the RT anterior axillary line 8 th intercostal space.picture taken , the unique , novality of this modility is the diagnosis of fibrosis too like liver.Grading of aftty pancreas was done as well as fibrosis of pancreas as follow :S1 =264 dB/m , S2 =276 dB/m and S3 =336 dB/m .

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged from 30 to 70 years old , both male and females , DM or not obese or non obese

Exclusion criteria

  • Exclusion Criteria:
  • Subjects with significant amount of alcohol consumption or history of alcohol consumption (>60 g/day).
  • History of steatogenic medications (amiodarone, valproic acid, corticosteroids, tetracyclines).
  • Patients with a previous history of pancreatic disease

-

Treatment and study plan

meeting about the nutrition

Device

In the meeting time abou the nutrition we talk about our ancient egyptian food which confirmed with Carton already present at center of excellence ,

Primary outcomes

  1. prevelance of fatty pancreas 60% which is more common than the expection

    Time frame: 6 months

    the need to raise uo the importance to use FibroScan to diagnosis of fatty pancreas which is novel , unique and invasive , specific

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

A Study About the Role of Gut Microbiome in Fatty Liver -Fatty Pancreas and Heart Diseases .

Acronym: FattyPancreas

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 1, 2025
Registry last updated
Dec 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.